Condition: Familial Hypercholesterolemia - Heterozygous · Sponsor: Novartis Pharmaceuticals
This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in children (aged 6 to \<12 years) with heterozygous familial hypercholesterolemia (HeFH) and elevated low density lipoprotein cholesterol (LDLC).
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · +41613241111
Always discuss trial participation with your own doctor first.
| UC San Francisco Medical Center | San Francisco, California, United States | Recruiting |
| UC San Francisco Medical Center | San Francisco, California, United States | Recruiting |
| Children's National Hospital | Washington D.C., District of Columbia, United States | Not Yet Recruiting |
| Childrens National Hospital | Washington D.C., District of Columbia, United States | Recruiting |
| Excel Medical Clinical Trials LLC | Boca Raton, Florida, United States | Recruiting |
| Icahn School of Med at Mt Sinai | New York, New York, United States | Recruiting |
| Primary Childrens Medical Center | Salt Lake City, Utah, United States | Not Yet Recruiting |
| Primary Childrens Medical Center | Salt Lake City, Utah, United States | Recruiting |
| Virginia Commonwealth University | Richmond, Virginia, United States | Recruiting |
| West Virginia Childrens Hospital | Morgantown, West Virginia, United States | Recruiting |
| West Virginia Childrens Hospital | Morgantown, West Virginia, United States | Recruiting |
| Novartis Investigative Site | Buenos Aires, Argentina | Recruiting |
+ 54 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06597019